Sionna director granted option on 17,340 shares
Sionna Therapeutics director Bruce Booth received a grant of 17,340 non-qualified stock options to buy common stock at $36.73 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sionna Therapeutics director Bruce Booth received a grant of 17,340 non-qualified stock options to buy common stock at $36.73 per share. The options expire on June 16, 2036 and vest in full on the earlier of June 17, 2027 or the next annual meeting, subject to his continued service. Any proceeds from future sales of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Booth disclaims ownership except for any pecuniary interest.
Insider Trade Summary
Grant/Award: 17,340 shares
Grant/Award
1 txn
Insider
Booth Bruce
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 17,340 contracts (Direct)
Footnotes (2)
- F1. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
- F2. This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
Key Figures
Option grant size: 17,340 options
Exercise price: $36.73 per share
Expiration date: June 16, 2036
+3 more
6 metrics
Option grant size
17,340 options
Non-qualified stock options granted to director
Exercise price
$36.73 per share
Conversion or exercise price of granted options
Expiration date
June 16, 2036
Option term end date
Underlying shares
17,340 shares
Common stock underlying the option grant
Post-transaction derivative holdings
17,340 options
Total derivative securities following the grant
Transaction code
A
Grant, award, or other acquisition under Section 16
Key Terms
Non-Qualified Stock Option (right to buy), Section 16 of the Securities Exchange Act of 1934, pecuniary interest, annual meeting, +1 more
5 terms
Non-Qualified Stock Option (right to buy) financial
"security_title: "Non-Qualified Stock Option (right to buy)""
Section 16 of the Securities Exchange Act of 1934 regulatory
"disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
annual meeting financial
"vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
vesting financial
"This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sionna Therapeutics (SION) report for Bruce Booth?
Sionna Therapeutics reported a stock option grant to director Bruce Booth. He received 17,340 non-qualified stock options to purchase common stock at $36.73 per share, providing equity-based compensation tied to the company’s future share performance rather than a cash payment today.
What are the key terms of Bruce Booth’s Sionna Therapeutics (SION) option grant?
Bruce Booth’s option grant covers 17,340 shares at a $36.73 exercise price. The non-qualified stock options expire on June 16, 2036 and relate to common stock, giving him the right, but not the obligation, to buy shares at that fixed price once vested.
When do Bruce Booth’s Sionna Therapeutics (SION) options vest?
The options vest in full on the earlier of two dates. Vesting occurs on June 17, 2027 or on the date of the next annual meeting of Sionna Therapeutics, whichever comes first, provided Booth continues to serve as a director through the applicable vesting date.
How long do Bruce Booth’s Sionna Therapeutics (SION) options remain exercisable?
The granted options remain exercisable until June 16, 2036. After that expiration date, any unexercised options will lapse. This long-term duration is typical for director equity awards, aligning potential value with the company’s performance over many years.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates